The burgeoning popularity of retatrutide, initially for metabolic conditions, is creating significant buzz within the United Kingdom , prompting a notable shift in hormone trends. Obtaining these medications remains a complex landscape, with NHS provision currently limited and private clinics offering therapy at a substantial price. Concerns are be